SOCIAL AND CLINICAL CHARACTERISTICS OF PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCE

A retrospective analysis of medical records of 581 patients with non-muscle-invasive bladder cancer was carried out. Out of these patients, there were 467 men and 114 women, with a male-to-female ratio of 4:1. Among males, the highest incidence of non-muscle-invasive bladder cancer occurred in age range 45–59 year followed by age groups 60‑74 and 18‑44 years, representing 45.8 %, 33.4 %, and 16 %, respectively. For females, the highest incidence rate was observed in the 60 to 74 age group (58.7 %). Women aged 45‑59 and 75‑90 years represented 26.5 % and 14.3 %, respectively. The proportion of women aged 45‑49 years was almost half the proportion of men of this age group. Among female patients, there were very few women under 44 years. The vast majority of patients were residents of the Central Federal District with a primary residence in Moscow and the Moscow region. Both male and female patients were more susceptible to negative effects of smoking. Both male and female patients experienced occupational exposure to chemical carcinogens, with 3:1 male predominance. Men represented a higher proportion of those who received radiation therapy as compared to women (3.2 % versus 1.9 %). The bladder wall was the most frequent site of tumor location. The bladder fundus invasion occurred two times less frequently. The frequency of the bladder neck and apex invasion was 13 % and 9 %, respectively. Multicentric bladder cancer was observed in 6 % of the patients. Grade 1 cancer was the most common (53 %) followed by grade 2 and grade 3 (29 % and 18 %, respectively). According to results obtained, the studied cohort demonstrates the main social and clinical characteristics for patients with non-muscle-invasive bladder cancer.

non-muscle-invasive bladder cancer, risk factors, medical-social characteristics

1. Ploeg M., Aben K.K., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009 Jun; 27 (3): 289–93. doi: 10.1007/s00345 009 0383 3.

2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013 Jan; 63 (1): 11–30. doi: 10.3322/caac.21166.

3. Fajkovic H., Halpern J.A., Cha E.K., Bahadori A., Chromecki T.F., Karakiewicz P.I., Breinl E., Merseburger A.S., Shariat S.F. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol. 2011 Aug; 29 (4): 457–63. doi: 10.1007/s00345 011 0709 9.

4. Abdollah F., Gandaglia G., Thuret R., Schmitges J., Tian Z., Jeldres C., Passoni N.M., Briganti A., Shariat S.F., Perrotte P., Montorsi F., Karakiewicz P.I., Sun M. Incidence, survival and mortality rates of stage specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013 Jun; 37 (3): 219–25. doi: 10.1016/j.canep.2013.02.002.

5. Sylvester R.J., van der Meijden A.P., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., Newling D.W., Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar; 49 (3): 466–5; discussion 475–7.

6. Fernandez-Gomez J., Madero R., Solsona E., Unda M., Martinez-Piñeiro L., Gonzalez M., Portillo J., Ojea A., Pertusa C., Rodriguez-Molina J., Camacho J.E., Rabadan M., Astobieta A., Montesinos M., Isorna S., Muntañola P., Gimeno A., Blas M., Martinez-Piñeiro J.A. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette Guerin: the CUETO scoring model. J Urol. 2009; 182 (5): 2195–203. doi: 10.1016/j.juro.2009.07.016.

7. Epstein J.I., Amin M.B., Reuter V.R., Mostofi F.K. The World Health Organization. International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998 Dec; 22 (12): 1435–48.

8. Glantz S. Medico biological statistics. Moscow, 1999. 467. [in Russian]

9. Cárdenas-Turanzas M., Cooksley C., Pettaway C.A., Sabichi A., Grossman H.B., Elting L. Comparative outcomes of bladder cancer. Obstet. Gynecol. 2006; 108 (1): 169–175.

10. Burger M., Catto J.W., Dalbagni G., Grossman H.B., Herr H., Karakiewicz P., Lotan Y. Epidemiology and risk factors of urothe lial bladder cancer. Eur Urol. 2013; 63 (2): 234–241. doi: 10.1016/j. eururo.2012.07.033.

11. Freedman N.D., Silverman D.T., Hollenbeck A.R., Schatzkin A., Abnet C.C. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011 Aug 17; 306 (7): 737–45. doi: 10.1001/ jama.2011.1142.

12. Gandini S., Botteri E., Iodice S., Boniol M., Lowenfels A.B., Maisonneuve P., Boyle P. Tobacco smoking and cancer: a meta analysis. Int J Cancer. 2008 Jan 1; 122 (1): 155–64.

13. Harling M., Schablon A., Schedlbauer G., Dulon M., Nienhaus A. Bladder Cancer among hairdressers: a meta analysis. Occup Environ Med. 2010 May; 67(5): 351–8. doi: 10.1136/oem.2009.050195.

14. Weistenhofer W., Blaszkewicz M., Bolt H.M., Golka K. N acetyl transferase 2 and medical history in bladder cancer cases with a suspected occupational disease (BK 1301) in Germany. J Toxicol Environ Health A. 2008; 71 (13–14): 906–10. doi: 10.1080/15287390801988681.

15. Zelefsky M.J., Housman D.M., Pei X., Alicikus Z., Magsanoc J.M., Dauer L.T., St Germain J., Yamada Y., Kollmeier M., Cox B., Zhang Z. Incidence of secondary cancer development after high dose intensity modulated radiotherapy and image guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 1; 83 (3): 953–9. doi: 10.1016/j.ijrobp.2011.08.034.

16. Nieder A.M., Porter M.P., Soloway M.S. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol. 2008 Nov; 180 (5): 2005–9; discus sion 2009–10. doi: 10.1016/j.juro.2008.07.038.